Sonnet BioTherapeutics (SONN) Registration Filing summary

Offering details and pricing

• The offering consists of 1,103,752 shares of common stock, 1,103,752 pre-funded warrants, and 2,207,504 common warrants, with each share or pre-funded warrant sold together with a warrant to purchase two shares of common stock at an exercise price of $4.53 per share.

• The assumed combined public offering price is $4.53 per share, based on the last reported sale price on October 31, 2024.

• Net proceeds are estimated at $4.4 million, after underwriting discounts, commissions, and offering expenses, excluding any proceeds from warrant exercises.

• The offering is underwritten by Chardan Capital Markets, LLC, with a 7% commission and a 1% non-accountable expense allowance.

• The common stock is listed on Nasdaq under the symbol "SONN"; there is no public market for the pre-funded or common warrants.

Company overview and business model

• The company is a clinical-stage, oncology-focused biotechnology firm leveraging a proprietary Fully Human Albumin Binding (FHAB) platform to develop biologic medicines with single or bifunctional action.

• The platform is designed to improve drug accumulation in tumors and lymph nodes, extend drug activity, and reduce immunogenicity.

• Lead programs include SON-1010 (IL-12-FHAB) for solid tumors and platinum-resistant ovarian cancer, and SON-080 (IL-6) for chemotherapy-induced and diabetic peripheral neuropathy.

• The company operates with a lean internal structure, utilizing a network of outsourced vendors and strategic collaborations to optimize costs and execution timelines.

Financial performance and metrics

• Net losses were $4.3 million for the nine months ended June 30, 2024, and $18.8 million for the year ended September 30, 2023.

• As of June 30, 2024, cash was $3.6 million, with an accumulated deficit of $114.6 million.

• Research and development expenses were $4.5 million for the nine months ended June 30, 2024, down from $10.0 million in the prior year period, reflecting cost-saving initiatives and program prioritization.

• The company expects its cash position, together with proceeds from this offering and other anticipated receipts, to fund operations into March 2025.